Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Primo Brands Corporation regarding a class action lawsuit due to alleged false statements and supply disruptions following the merger with BlueTriton Brands [1][2]. Group 1: Allegations and Issues - The class action alleges that the defendants made false statements and concealed poor integration tracking of the merger between Primo Water and BlueTriton Brands, citing technology and service issues as contributing factors [2]. - Contrary to the defendants' claims of a "flawless" execution, significant supply disruptions were reported, which negatively impacted customers and the financial results of Primo Brands [2]. Group 2: Class Action Details - The class period for the lawsuit is from June 17, 2024, to November 6, 2025, and shareholders are encouraged to register for participation [2][3]. - The deadline for shareholders to seek lead plaintiff status is January 12, 2026, with no cost or obligation to participate in the case [3]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of James Hardie Industries plc regarding a class action lawsuit due to alleged false statements and concealed adverse facts about the company's North America segment [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that James Hardie's North America segment faced deteriorating primary consumer demand and growth [1]. - It is claimed that overstocking was the main driver of growth in the North America segment during the class period, rather than genuine consumer demand [1]. - Excessive inventory at James Hardie's North America distributors is cited as a consequence of these issues [1]. Class Period and Registration - The class period for the allegations is from May 20, 2025, to August 18, 2025 [1]. - Shareholders are encouraged to register for the class action by December 23, 2025, to potentially be appointed as lead plaintiffs [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [1][3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Drug Candidate Details - MoonLake promoted SLK as a breakthrough treatment due to its Nanobody structure but allegedly failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Trial Results and Market Impact - On September 28, 2025, MoonLake disclosed that SLK did not meet efficacy benchmarks in Phase 3 trials, leading to a significant stock price decline of $55.75 per share, nearly 90%, in one trading session [4].

Core Viewpoint - Stride, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and non-compliance with legal requirements during the class period from October 22, 2024, to October 28, 2025 [1][3]. Allegations Against Stride - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students" and cut staffing costs by overloading teachers beyond statutory limits [3]. - Stride is accused of ignoring compliance requirements, including background checks and licensure laws, and failing to provide federally mandated special education services [3]. - The company allegedly suppressed whistleblowers who reported financial directives aimed at preserving profit margins by delaying hiring and denying services [3]. - Stride reportedly lost existing and potential enrollments due to these practices [3]. Impact of Legal Issues - A complaint filed by the Gallup-McKinley County Schools Board of Education against Stride on September 14, 2025, led to a nearly 12% drop in Stride's stock price [4]. - Following an announcement on October 28, 2025, regarding "poor customer experience" leading to higher withdrawal rates and an estimated loss of 10,000-15,000 enrollments, Stride's stock price fell more than 54% [5]. Class Action Process - Investors who purchased Stride securities during the class period can seek appointment as lead plaintiff in the lawsuit, representing the interests of the class [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been recognized for securing significant monetary relief for investors, including the largest recovery in history of $7.2 billion in the Enron case [7].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop of approximately 20% after disappointing financial results and the unexpected departure of its CEO [1][6][7]. Financial Performance - CarMax reported a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units for the second quarter of fiscal year 2026 [6]. - The company's net income for the second quarter was approximately $95.4 million, down from $132.8 million in the previous year [6]. - The stock price fell from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025, a drop of $11.45 per share or roughly 20% [7]. Legal Issues - A class action lawsuit has been filed against CarMax and certain senior executives under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - The lawsuit claims that CarMax misrepresented the demand for its cars, which was allegedly boosted by short-term factors such as U.S. tariffs [4]. - The unexpected departure of CEO Bill Nash on November 6, 2025, is also under investigation regarding the company's assessment of its car loan portfolio [5].

Core Viewpoint - MoonLake Immunotherapeutics (MLTX) is facing securities fraud allegations after a significant stock price drop of nearly 90%, prompting investors to seek legal recourse [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company was conducting Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa (HS) [4]. Group 2: Allegations and Legal Action - A lawsuit has been filed against MoonLake and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - The complaint claims that MoonLake misrepresented its clinical data and the advantages of its Nanobody structure over competitors, which undermined the drug's regulatory approval and commercial viability [6]. Group 3: Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted from $61.99 per share to $6.24 per share, a decline of $55.75 or nearly 90% [7].

Core Viewpoint - Stride, Inc. is facing a class action lawsuit for securities fraud following a significant drop in its stock price, attributed to alleged violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" to secure state funding and ignored compliance requirements, leading to a poor customer experience [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60 per share, or over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, or more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Investor Actions - Investors in Stride are encouraged to seek additional information and may have legal options available [2][7].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% decline year-over-year. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Customer Dynamics - The lawsuit alleges that while Synopsys claimed its customers relied on its IP to minimize integration risk and speed time to market, the reality was that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys' stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].

Core Points - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][2] - The lawsuit claims that Stride inflated enrollment numbers and failed to comply with legal requirements, leading to a poor customer experience and higher withdrawal rates [3][4] Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3] - The company previously reported increasing growth and strong demand for its products and services [3] Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60 per share (over 11%) following allegations of fraud and deceptive practices, falling from $158.36 to $139.76 [4] - On October 28, 2025, Stride acknowledged issues with customer experience, leading to an estimated loss of 10,000-15,000 enrollments and a subsequent stock drop of $83.48 per share (over 54%), from $153.53 to $70.05 [5]

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6].